An assessment of change in asthma control among adolescents and adults with persistent asthma in mometasone furoate/formoterol fumarate clinical trials.
Wyrwich
Kathleen W
KW
United BioSource Corporation, Bethesda, MD 20814, USA. kathy.wyrwich@unitedbiosource.com
Ireland
Andrea M
AM
Navaratnam
Prakash
P
Nolte
Hendrik
H
Gates
Davis F
DF
D000280:Administration, Inhalation; D000293:Adolescent; D058666:Adrenergic beta-2 Receptor Agonists / Q000008:administration & dosage*; D000328:Adult; D018927:Anti-Asthmatic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology*; D001993:Bronchodilator Agents / Q000008:administration & dosage*; D002648:Child; D004359:Drug Therapy, Combination; D004983:Ethanolamines / Q000008:administration & dosage*; D005260:Female; D000068759:Formoterol Fumarate; D006801:Humans; D008297:Male; D000068656:Mometasone Furoate; D010366:Peak Expiratory Flow Rate; D011244:Pregnadienediols / Q000008:administration & dosage*; D011594:Psychometrics; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic; D011795:Surveys and Questionnaires; D014797:Vital Capacity
D058666:Adrenergic beta-2 Receptor Agonists; D018927:Anti-Asthmatic Agents; D001993:Bronchodilator Agents; D004983:Ethanolamines; D011244:Pregnadienediols; D000068656:Mometasone Furoate; D000068759:Formoterol Fumarate